INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 166 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q2 2018. The put-call ratio across all filers is 0.65 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2018 | $3,372,000 | +66.3% | 26,688 | +10.4% | 0.71% | +15.3% |
Q2 2018 | $2,028,000 | +11.7% | 24,174 | -18.1% | 0.62% | +53.6% |
Q1 2018 | $1,816,000 | +3.1% | 29,511 | -2.1% | 0.40% | +2.3% |
Q4 2017 | $1,761,000 | +21912.5% | 30,147 | +60194.0% | 0.39% | +19500.0% |
Q3 2015 | $8,000 | – | 50 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Sarissa Capital Management LP | 635,300 | $53,308,000 | 10.69% |
Senvest Management, LLC | 976,127 | $81,907,000 | 5.65% |
Melqart Asset Management (UK) Ltd | 390,600 | $32,775,000 | 2.80% |
Asymmetry Capital Management, L.P. | 25,918 | $2,175,000 | 2.14% |
Elk Creek Partners, LLC | 386,397 | $32,423,000 | 1.78% |
BB BIOTECH AG | 545,719 | $45,791,000 | 1.32% |
ALTRINSIC GLOBAL ADVISORS LLC | 383,166 | $32,151,000 | 1.27% |
DLD Asset Management, LP | 129,000 | $10,824,000 | 0.82% |
Opus Point Partners Management, LLC | 3,998 | $335,000 | 0.73% |
Virtus ETF Advisers LLC | 8,970 | $753,000 | 0.67% |